Kyowa Kirin Co., Ltd. announced that the European Medicines Agencys Committee for Medicinal Products for Human Use issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinsons, experiencing end-of-dose motor fluctuations. Kyowa Kirin International remain committed to istradefylline and people living with Parkinsons and are currently reviewing the options available, which may include re-examination. The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
Istradefylline is a novel, first-in-class non-dopaminergic, adenosine A2A receptor antagonist that reduces OFF time in people living with Parkinsons through selective targeting of adenosine A2A receptors in the basal ganglia. Whilst dopaminergic treatment targets the dopamine receptors in the direct and indirect pathways to facilitate movement, istradefylline, as an add-on to L-Dopa, reduces the activity of the indirect pathway which suppresses movement. Therefore, it helps restore the balance within the basal ganglia.